natgillin/translations-raw huggingface dataset:
I disse farmakokinetiske forsøg var eksponering for atazanavir 300 mg med cobicistat 150 mg den samme som eksponeringen, når det blev boostet med ritonavir 100 mg. EVOTAZ er bioækvivalent med atazanavir 300 mg 1 gang dagligt i kombination med cobicistat 150 mg 1 gang dagligt administreret som enkeltdosis (se pkt. 
In these pharmacokinetic trials, the exposure of atazanavir 300 mg with cobicistat 150 mg was consistent with that observed when boosted with ritonavir 100 mg. EVOTAZ is bioequivalent to atazanavir 300 mg once daily in combination with cobicistat 150 mg once daily coadministered as single agents (see section 5.2).
Rifampicin nedsætter i væsentlig grad plasmakoncentrationerne af atazanavir, hvilket kan medføre tab af EVOTAZ's terapeutiske effekt og udvikling af resistens over for atazanavir. 
Rifampicin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir.
Denne indlægsseddel blev senest ændret <{MM/ÅÅÅÅ}> <{måned ÅÅÅÅ}.> 
This leaflet was last revised in.
Denne effekt kan skyldes CYP3A4induktion. 
This effect may be due to an induction of CYP3A4.
Øget monitorering for bivirkninger anbefales. 
Increase monitoring for adverse reactions.
Samtidig brug af EVOTAZ og kortikosteroider, der metaboliseres via CYP3A (f.eks. fluticasonpropionat eller andre inhalerede eller nasale kortikosteroider) kan øge risikoen for udvikling af systemiske kortikosteroidvirkninger, herunder Cushings syndrom og binyrebarksuppression. 
Concomitant use of EVOTAZ and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.
Lægemidler, der kan påvirkes af atazanavir/cobicistat Atazanavir er en CYP3A4- og UGT1A1-hæmmer. 
Medicinal products that may be affected by atazanavir/cobicistat Atazanavir is an inhibitor of CYP3A4 and UGT1A1.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver filmovertrukket tablet indeholder atazanavirsulfat svarende til 300 mg atazanavir og 150 mg cobicistat. 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains atazanavir sulphate corresponding to 300 mg atazanavir and 150 mg of cobicistat.
Mave-tarm-kanalen meget almindelig kvalme almindelig opkastning, diarre, dyspepsi, mavesmerter, abdominal distension, flatulens, mundtørhed ikke almindelig pankreatitis, gastritis, aftøsstomatitis 
Gastrointestinal disorders very common nausea common vomiting, diarrhoea, dyspepsia, abdominal pain, abdominal distension, flatulence, dry mouth uncommon pancreatitis, gastritis, stomatitis aphthous
Der foreligger ingen farmakokinetiske data for atazanavir i kombination med cobicistat hos patienter med nyreinsufficiens. 
There are no pharmacokinetic data available for atazanavir in combination with cobicistat in patients with renal insufficiency.
Laboratoriemæssige anormaliteter 
Laboratory abnormalities
Atazanavir med cobicistatf 
Atazanavir with cobicistatf
Kontakt lægen, hvis du lægger mærke til ændringer i dit helbred. 
Tell your doctor if you notice anything unusual about your health.
Der er utilstrækkelige kliniske data fra anvendelsen af cobicistat til gravide kvinder. 
There are limited clinical data with cobicistat in pregnant women.
Plasmakoncentrationerne af atazanavir kan falde pga. gastrisk pH-stigning, hvis antacida, inklusive lægemidler med buffer, administreres samtidigt med EVOTAZ. 
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with EVOTAZ.
Interaktionsmekanismen mellem efavirenz og atazanavir eller efavirenz og cobicistat er efavirenzs CYP3A4-induktion. 
The mechanism of interaction between efavirenz and atazanavir, or efavirenz and cobicistat is CYP3A4 induction by efavirenz.
Voriconazol bør ikke administreres sammen med EVOTAZ, medmindre det vurderes, at fordel/risiko-forholdet for patienten berettiger brug af voriconazol (se pkt. 
Voriconazole should not be co-administered with EVOTAZ unless the benefit/risk assessment justifies the use of voriconazole (see section 4.4).
Udslæt er ofte lette til moderate makulopapuløse huderuptioner, der optræder inden for de første 3 uger efter påbegyndelse af behandling med atazanavir, et af indholdsstofferne i EVOTAZ. 
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with atazanavir, a component of EVOTAZ.
Der er i kliniske studier observeret dosisrelaterede, asymptomatiske forlængelser i PR-intervallet med atazanavir, som er et indholdsstof i EVOTAZ. 
Dose related asymptomatic prolongations in PR interval with atazanavir, a component of EVOTAZ have been observed in clinical studies.
Hyppigere monitorering af terapeutiske koncentrationer anbefales for disse immunsuppressiva ved samtidig administration af EVOTAZ. 
More frequent therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with EVOTAZ.
Der er risiko for manglende terapeutisk effekt og resistensudvikling over for atazanavir (se pkt. 
There is a risk of loss of therapeutic effect and development of resistance to atazanavir (see section 4.3).
Samtidig administration af bosentan og cobicistat kan medføre nedsatte plasmakoncentrationer. 
Co-administration of bosentan with cobicistat may lead to decreased cobicistat plasma concentrations.
Interaktionsmekanismen er atazanavirs hæmning af metabolisme. 
The mechanism of interaction is inhibition of metabolism by atazanavir.
Samtidig administration af EVOTAZ kan medføre øget koncentration af PDE5-hæmmeren og øget risiko for PDE5-relaterede bivirkninger, inklusive hypotension, synsforstyrrelser og priapisme. 
Co-administration with EVOTAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism.
Atazanavir og fluconazol-koncentrationer ændredes ikke signifikant ved samtidig administration af atazanavir/ritonavir og fluconazol. 
Atazanavir and fluconazole concentrations were not significantly modified when atazanavir/ritonavir was co-administered with fluconazole.
EVOTAZ bør anvendes med forsigtighed til patienter med allerede eksisterende overledningsproblemer (anden grads- eller højere atrioventrikulær eller kompleks knude-grenblok), og kun såfremt fordelene opvejer risikoen (se pkt. 
In patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), EVOTAZ should be used with caution and only if the benefits exceed the risk (see section 5.1).
Koncentrationen af fluconazol kan øges ved samtidig administration af cobicistat. 
Concentration of fluconazole may be increased if co-administered with cobicistat.
EVOTAZ er en pink, oval, bikonveks, filmovertrukket tablet med omtrentlige dimensioner på 19 mm x 10,4 mm og præget med ”3641” på den ene side og glat på den anden side. 
What EVOTAZ looks like and contents of the pack EVOTAZ tablets are pink, oval, biconvex, film coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed on one side with "3641" and plain-faced on the other side of the tablet.
Dosisjustering er ikke nødvendig for raltegravir ved samtidig administration med EVOTAZ. 
No dose adjustment is required for raltegravir if co-administered with EVOTAZ.
EVOTAZ kan påvirke din nyrefunktion. 
EVOTAZ may affect how well your kidneys work.
EVOTAZ bør anvendes med forsigtighed hos patienter med let nedsat leverfunktion. 
EVOTAZ should be used with caution in patients with mild hepatic impairment.
Se produktresuméet for REYATAZ for flere oplysninger. 
For more information consult the REYATAZ Summary of Product Characteristics.
EVOTAZ bør ikke initieres hos patienter med kreatininclearance under 70 ml/min, hvis en eller flere af samtidigt administrerede lægemidler dosisjusteres på baggrund af kreatininclearance (f.eks. emtricitabin, lamivudin, tenofovirdisoproxil eller adefovir; se pkt. 
EVOTAZ should not be initiated in patients with creatinine clearance less than 70 ml/min if one or more co-administered agent requires dose adjustment based on creatinine clearance (e.g. emtricitabine, lamivudine, tenofovir disoproxil or adefovir; see sections 4.2, 4.8 and 5.2).
Blandt behandlingsnaive patienter, der fik atazanavir 300 mg én gang dagligt med 100 mg ritonavir én gang dagligt med en median behandlingsvarighed på 96 uger, havde 48% grad 3-4 forhøjelse af total-bilirubin (se pkt. 
Among naïve patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 96 weeks, 48% had Grade 3-4 total bilirubin elevations (see section 4.4).
Samtidig administration af simvastatin eller lovastatin og EVOTAZ er kontraindiceret på grund af øget risiko for myopati, inklusive rabdomyolyse (se pkt. 
Co-administration of simvastatin or lovastatin with EVOTAZ is contraindicated due to an increased risk of myopathy including rhabdomyolysis (see section 4.3).
Samtidig administration af etravirin og EVOTAZ forventes at nedsætte atazanavir- og cobicistat-plasmakoncentrationerne. 
Co-administration of etravirine and EVOTAZ is expected to decrease atazanavir and cobicistat plasma concentrations.
Lever og galdeveje meget almindelig gulsot almindelig hyperbilirubinæmi ikke almindelig hepatitis, cholelithiasisa, kolestasea sjælden hepatosplenomegali, cholecystitisa 
Hepatobiliary disorders very common jaundice common hyperbilirubinaemia uncommon hepatitis, cholelithiasisa, cholestasisa rare hepatosplenomegaly, cholecystitisa
Dette kan medføre tab af EVOTAZ's terapeutiske effekt og udvikling af resistens over for atazanavir (se pkt. 
This may result in loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir (see section 4.4).
Atazanavir metaboliseres primært via leveren, og der er observeret forhøjede plasmakoncentrationer hos patienter med nedsat leverfunktion (se pkt. 
Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 5.2).
Koncentrationen af disse calciumkanalblokkere kan øges ved samtidig administration af EVOTAZ. 
Concentrations of these calcium channel blockers may be increased when co-administered with EVOTAZ.
Samtidig administration af EVOTAZ og lægemidler, der indeholder ritonavir eller cobicistat, som er kraftige CYP3A-hæmmere, kan resultere i yderligere boosting og øget plasmakoncentration af atazanavir. 
Co-administration of EVOTAZ with medicinal products containing ritonavir or cobicistat, which are strong inhibitors of CYP3A, may result in additional boosting and increased plasma concentration of atazanavir.
Nyrer og urinveje ikke almindelig nephrolithiasisa, hæmaturi, proteinuri, pollakisuri, interstitiel nefritis, kronisk nyresygdoma sjælden nyresmerter 
Renal and urinary disorders uncommon nephrolithiasisa, haematuria, proteinuria, pollakiuria, interstitial nephritis, chronic kidney diseasea rare kidney pain
Mekanismen bag dette fald er ukendt (se pkt. 
The mechanism of this decrease is unknown (see sections 4.2 and 4.4.)
Koncentrationen af disse sedativa/hypnotika kan øges ved samtidig administration af EVOTAZ. 
Concentrations of these sedatives/hypnotics may be increased when co-administered with EVOTAZ.
En filmovertrukket tablet indeholder 300 mg atazanavir (som sulfat) og 150 mg cobicistat. 
Each film-coated tablet contains 300 mg of atazanavir (as sulphate), and 150 mg cobicistat.
Tabletkerne mikrokrystallinsk cellulose (E460(i)) croscarmellosenatrium (E468) natriumstivelsesglycolat crospovidon (E1202) stearinsyre (E570) magnesiumstearat (E470b) hydroxypropylcellulose (E463) silica (E551) 
Tablet core microcrystalline cellulose (E460(i)) croscarmellose sodium (E468) sodium starch glycolate crospovidone (E1202) stearic acid (E570) magnesium stearate (E470b) hydroxypropyl cellulose (E463) silicon dioxide (E551)
Interaktion er ikke undersøgt, hvad angår indholdsstofferne i EVOTAZ. 
Interaction not studied with any of the components of EVOTAZ.
Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle på grund af køn for hverken atazanavir eller cobicistat. 
No clinically relevant pharmacokinetic differences due to gender have been identified for atazanavir or cobicistat.
Tag ikke EVOTAZ: hvis du er allergisk over for atazanavir, cobicistat eller et af de øvrige indholdsstoffer i EVOTAZ (angivet i afsnit 6) 
Do not take EVOTAZ: if you are allergic to atazanavir, cobicistat or any of the other ingredients of this medicine (listed in section 6) if you have moderate to severe liver problems if you are taking any of these medicines: see also Other medicines and EVOTAZ
Der er anden medicin, som du ikke må tage samtidig med EVOTAZ eller som skal indgives på anden vis, når de tages samtidigt med EVOTAZ. 
There are other medicines that may not be taken together or may require a change in their mode of administration when taken with EVOTAZ.
Eftersom atazanavir er et af indholdsstofferne i EVOTAZ, frarådes samtidig administration af EVOTAZ og nevirapin eller efavirenz (se pkt. 
Because atazanavir is a component of EVOTAZ, co-administration of EVOTAZ with nevirapine or efavirenz is not recommended (see section 4.5).
EVOTAZ forventes at øge simeprevir plasmakoncentrationerne. 
EVOTAZ is expected to increase simeprevir plasma concentrations.
EVOTAZ må ikke anvendes til patienter med moderat til svært nedsat leverfunktion (se pkt. 
EVOTAZ must not be used in patients with moderate to severe hepatic impairment (see section 4.3).
EVOTAZ frarådes til samtidig administration med etravirin, da det kan medføre tab af terapeutisk effekt og udvikling af resistens over for atazanavir. 
EVOTAZ is not recommended for co-administration with etravirine because it may result in the loss of therapeutic effect and development of resistance to atazanavir.
Cobicistat er en svag CYP2D6-hæmmer og metaboliseres i mindre grad af CYP2D6. 
Cobicistat is a weak CYP2D6 inhibitor and is metabolised to a minor extent by CYP2D6.
Samtidig administration af EVOTAZ og lægemidler, som er moderat til svage CYP3A-induktorer kan resultere i nedsat plasmakoncentration af atazanavir og/eller cobicistat, hvilket medfører tab af terapeutisk effekt og mulig udvikling af resistens over for atazanavir. 
Co-administration of EVOTAZ with medicinal products that are moderate to weak inducers of CYP3A may result in decreased plasma concentration of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir.
Samtidig administration med EVOTAZ kan medføre øget koncentration af PDE5-hæmmeren og øget antal bivirkninger relateret til PDE5-hæmmeren. 
Co-administration with EVOTAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5 inhibitor-associated adverse events.
Disse lægemidler omfatter alfuzosin, amiodaron, astemizol, bepridil, cisaprid, colchicin, dronedaron, ergotaminderivater (f.eks. dihydroergotamin, ergometrin, ergotamin, methylergonovin), lovastatin, oralt administreret midazolam, pimozid, quetiapin, quinidin, lurasidon, simvastatin, sildenafil (når det anvendes til behandling af pulmonal arteriel hypertension), avanafil, systemisk lidocain, ticagrelor, terfenadin og triazolam. 
These medicinal products include alfuzosin, amiodarone, astemizole, bepridil, cisapride, colchicine, dronedarone, ergot deriviatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine), lovastatin, orally administered midazolam, pimozide, quetiapine, quinidine, lurasidone, simvastatin, sildenafil (when used to treat pulmonary arterial hypertension), avanafil, systemic lidocaine, ticagrelor, terfenadine and triazolam.
Midazolam og triazolam metaboliseres i udstrakt grad af CYP3A4. 
Midazolam and triazolam are extensively metabolized by CYP3A4.
Sofosbuvir 400 mg/velpatasvir, 100 mg/voxilaprevir 100 mg enkeltdosis* (atazanavir 300 mg med ritonavir 100 mg 1 gang dagligt) 
Sofosbuvir 400 mg/velpatasvir, 100 mg/voxilaprevir 100 mg single dose* (atazanavir 300 mg with ritonavir 100 mg once daily)
Samtidig administration af atorvastatin og EVOTAZ frarådes. 
Co-administration of atorvastatin with EVOTAZ is not recommended.
Samtidig administration af EVOTAZ og en protonpumpehæmmer frarådes. 
Co-administration of EVOTAZ with proton pump inhibitors is not recommended.
Samtidig administration af EVOTAZ med produkter indeholdende grazoprevir inklusive elbasvir/grazoprevir i fastdosiskombination (bruges til behandling af kronisk hepatitis C infektion) er kontraindiceret på grund af stigning i plasmakoncentrationerne af grazoprevir og elbasvir og den mulige forøgelse i risiko for ALAT-stigninger som er associeret med stigning i grazoprevirkoncentrationer (se pkt. 
Co-administration of EVOTAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with the increase in grazoprevir concentrations (see section 4.3 and Table 1).
Der er ikke udført interaktionsstudier med EVOTAZ. 
Drug interaction trials were not conducted for EVOTAZ.
Samtidig behandling med EVOTAZ og regimer indeholdende voxilaprevir frarådes. 
Coadministration of EVOTAZ with voxilaprevir-containing regimens is not recommended.
Koncentrationen af dabigatran kan være påvirket ved samtidig administration af EVOTAZ. 
Concentrations of dabigatran may be affected upon co-administration with EVOTAZ.
Atazanavir, som er et stof i EVOTAZ, udskilles i modermælken hos mennesker. 
Atazanavir, a component of EVOTAZ is excreted in human milk.
Filmovertræk hypromellose (hydroxypropylmethylcellulose, E464) titandioxid (E171) talcum (E553b) triacetin (E1518) rød jernoxid (E172) 
Film-coating hypromellose (hydroxypropyl methyl cellulose, E464) titanium dioxide (E171) talc (E553b) triacetin (E1518) red iron oxide (E172)
Behandling med EVOTAZ bør ikke påbegyndes hos patienter med kreatininclearance under 70 ml/min, hvis et eventuelt samtidigt administreret præparat (f.eks. emtricitabin, lamivudin, tenofovirdisoproxil eller adefovir) kræver dosisjustering baseret på kreatininclearance (se pkt. 
EVOTAZ should not be initiated in patients with creatinine clearance less than 70 ml/min if any co-administered agent (e.g. emtricitabine, lamivudine, tenofovir disoproxil or adefovir) requires dose adjustment based on creatinine clearance (see sections 4.4, 4.8 and 5.2).
Interaktionsmekanismen er nedsat opløselighed af atazanavir pga. intragastrisk pH-stigning med H2-blokkere. 
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2 blockers.
Samtidig administration af EVOTAZ har potentiale til at øge plasmakoncentrationerne af warfarin. 
Co-administration with EVOTAZ has the potential to increase warfarin plasma concentrations.
Maksimumkoncentration af digoxin øges ved samtidig administration af cobicistat. 
The peak concentration of digoxin is increased when co-administered with cobicistat.
Famotidin 20 mg to gange dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt) hos hiv-inficerede patienter 
Famotidine 20 mg twice daily (atazanavir 300 mg/ritonavir 100 mg once daily) in HIV-infected patients
Betydningen af nedsat leverfunktion for farmakokinetikken for atazanavir sammen med cobicistat er ikke undersøgt. 
The effects of hepatic impairment on the pharmacokinetics of atazanavir given with cobicistat have not been studied.
Interaktionsmekanismen er cobicistats CYP2D6-hæmning. 
The mechanism of interaction is inhibition of CYP2D6 by cobicistat.
Samtidig administration af EVOTAZ og nevirapin frarådes og kan medføre tab af EVOTAZ's terapeutiske effekt og udvikling af resistens over for atazanavir. 
Co-administration of EVOTAZ and nevirapine is not recommended and may result in a loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir.
Rifabutin 150 mg hver anden dag/elvitegravir 150 mg 1 gang dagligt/cobicistat 150 mg 1 gang dagligt 
Rifabutin 150 mg every other day/elvitegravir 150 mg once daily/cobicistat 150 mg once daily
Der foreligger ingen data for atazanavirs og cobicistats kombinerede farmakokinetik hos pædiatriske patienter. 
No data are available on the pharmacokinetics of atazanavir and cobicistat in combination in paediatric patients.
Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle på grund af etnisk oprindelse for hverken atazanavir eller cobicistat. 
No clinically relevant pharmacokinetic differences due to ethnicity have been identified for atazanavir or cobicistat.
Cobicistat er et CYP3A-substrat og metaboliseres i mindre grad af CYP2D6. 
Cobicistat is a CYP3A substrate and is metabolised to a minor extent by CYP2D6.
Klinisk signifikante interaktioner mellem EVOTAZ og CYP1A2-, CYP2B6-, CYP2C9- eller CYP2C19-substrater forventes ikke. 
Clinically significant interactions between EVOTAZ and substrates of CYP1A2, CYP2B6, CYP2C9 or CYP2C19 are not expected.
Du må ikke tage sildenafil sammen med EVOTAZ, hvis sildenafil anvendes til behandling af pulmonal arteriel hypertension (for højt blodtryk i lungernes blodkar). 
Do not take sildenafil with EVOTAZ when sildenafil is used for the treatment of pulmonary arterial hypertension.
Kombinationen af rifampicin og EVOTAZ er kontraindiceret (se pkt. 
The combination of rifampicin and EVOTAZ is contraindicated (see section 4.3).
Samtidig brug af EVOTAZ og lægemidler, der er kraftige CYP3A-induktorer (f.eks. carbamazepin, phenobarbital, phenytoin, rifampicin og prikbladet perikon [Hypericum perforatum]) kan resultere i nedsatte plasmakoncentrationer af atazanavir og/eller cobicistat, hvilket medfører tab af terapeutisk effekt og mulig udvikling af resistens over for atazanavir (se pkt. 
Co-administration of EVOTAZ with medicinal products that are strong inducers of CYP3A (such as carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John's wort [Hypericum perforatum]) may result in decreased plasma concentrations of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir (see section 4.3 and Table 1).
Patienter med blødersygdom (hæmofili A eller B) kan få øget blødning. 
People who already have type A or B haemophilia may notice increased bleeding.
Samtidig administration af EVOTAZ og elbasvir/grazoprevir er kontraindiceret på grund af en forventet stigning i plasmakoncentrationerne for grazoprevir og den associerede potentielle forøgelse i risiko for ALAT-stigninger (se pkt. 
Co-administration of EVOTAZ and elbasvir/grazoprevir is contraindicated because of the expected increase in grazoprevir plasma concentrations and the associated potential increase in the risk of ALT elevations (see section 4.3).
EVOTAZ forventes at øge rilpivirin plasmakoncentrationerne. 
EVOTAZ is expected to increase rilpivirine plasma concentrations.
Almindelige (kan forekomme hos op til 1 ud af 10 personer) øget appetit, smagsforstyrrelse, tør mund hovedpine, svimmelhed søvnbesvær, unormale drømme, døsighed (træthed) opkastning, diarre, mavesmerter, fordøjelsesbesvær, oppustethed, afgang af tarmluft (flatulens) forhøjede niveauer af bilirubin i blodet (hyperbilirubinæmi) udslæt voldsom træthed 
Common (may affect up to 1 in 10 people) increased appetite, dysgeusia (impairment of the sense of taste), dry mouth headache, dizziness insomnia (difficulty sleeping), abnormal dreams, somnolence (sleepiness) vomiting, diarrhoea, abdominal pain (stomach pain of discomfort), dyspepsia (indigestion), bloated or distended tummy (abdomen), flatulence (wind) hyperbilirubinaemia (increased levels of bilirubin in the blood) rash fatigue (extreme tiredness)
Samtidig administration af tenofovir DF og cobicistat forventes at øge plasmakoncentrationerne af tenofovir. 
Co-administration of tenofovir DF with cobicistat is expected to increase tenofovir plasma concentrations.
Amiodaron Dronedaron Quinidin 
Amiodarone Dronedarone Quinidine Systemic lidocaine